Menu
ncarol.com
  • Home
  • Music
  • Asheville Music
  • Entertainment
  • Real Estate
  • Business
  • Technology
  • Health
  • Books
ncarol.com

Prime Healthcare, EmVenio Research and Health Wizz Announce Strategic Partnership and Launch of EmVenio Research Center at Prime Healthcare
ncarol.com/10258250

Trending...
  • New Finnish Affiliate Site Ilmaiskierrokset.com Puts Wager-Free Spins in the Spotlight
  • Major FDA Victory; Preservative-Free Ketamine Approved Ahead of November 10 Goal Date as Commercial Launch Opportunity Comes Into Focus for NRx Pharma
  • RAS AP Consulting Advances 1099 Education and Readiness Initiative Through IFOL Training and Finance Technology Showcase
DURHAM, N.C., April 16, 2024 ~ Prime Healthcare and EmVenio Research have joined forces to launch the EmVenio Research Center at Prime Healthcare, a new initiative that aims to improve access to clinical research for patients while also expanding the research capabilities of Prime Healthcare hospitals.

EmVenio Research, a community research provider, will now have the opportunity to conduct research at Prime Healthcare hospitals and offer patients improved access to clinical trials. This partnership is expected to increase participation in clinical trials by creating awareness of research within communities and providing local access to global research opportunities.

With 44 hospitals and over 300 outpatient locations across the United States, Prime Healthcare is one of the nation's leading health systems. Known for its commitment to quality excellence and innovation, Prime Healthcare will provide the necessary infrastructure and clinical support for EmVenio Research to conduct advanced clinical trials.

Through this collaboration, EmVenio will work with Prime Healthcare hospitals to identify potential candidates for clinical trials using Health Wizz. This secure platform connects with Electronic Health Records (EHR) systems, protecting patient data while streamlining the process of identifying, screening, and enrolling study participants. All data collected will be kept secure and used only with patient consent.

More on ncarol.com
  • Arizona Pest Control Surpasses $200,000 in Contributions to Southern Arizona High School Sports and Education Programs
  • ZenaTech (NAS DAQ: ZENA) $1 Million in New Utility Contracts- Potential $2.5 Million Follow-On Opportunity Puts Its Drone Business in the Spotlight!
  • New Patient Data Show REQORSA® Activating Cellular Repair Pathways as Roche Collaboration Advances Precision Lung Cancer Strategy for Genprex, Inc
  • Genuine Hospitality, LLC Selected to Operate Holiday Inn Express & Suites Jacksonville – Town Center
  • Shiokly Launches Online Marketplace to Help Singapore Home-Based Businesses Sell More, With First Product Listed Free

Thad Wolfram, President of EmVenio Research, expressed his excitement about this partnership stating that their priority is delivering value to communities while successfully enrolling and retaining patients for their customers. He believes that through this collaboration with Prime Healthcare and Health Wizz, EmVenio will expand its community-based research footprint and be able to recruit an ever-growing patient base for clinical trials.

Dr. Sunny Bhatia, President and Chief Medical Officer of Prime Healthcare, also shared his enthusiasm about this partnership. He believes that EmVenio's expertise in designing and implementing clinical studies will keep the EmVenio Research Center at Prime Healthcare at the forefront of medical research and discovery. Dr. Bhatia hopes that by offering these opportunities to patients at Prime hospitals, they will have better clinical experiences and outcomes.

Nitin Desai, MD, President and Chief Medical Officer of Health Wizz, also expressed his pride in being a part of this visionary collaboration. He believes that by integrating their technology solutions, they can enhance the efficiency and security of enrolling study participants in clinical trials, ultimately benefiting both patients and researchers.

More on ncarol.com
  • Freight Broker 911 and Milton Collier Introduce "What's The 911?"—A New Podcast Built on Real Talk, Real Freight, and Real Opportunity
  • PropAccount.com Launches PropWallet, Turning Prop Firm Payouts Into Repeat Sales
  • Tonight in Asheville: KayeDinero Drops "Underground" and Opens Beat Catalog
  • KOLBUS America, For All Of Your Hycorr Equipment And Service Needs
  • Heritage at Hopewell Announces New 3.875% Year-One Mortgage Rate Buydown Incentive on Quick Delivery Townhomes (7.11% APR)

The EmVenio Research Center at Prime Healthcare will make clinical research available to patients at Prime hospitals across the country, starting with California, Alabama, Texas, and Georgia. This will provide clinical trial sponsors and Contract Research Organizations (CROs) with access to a large and diverse patient population that was previously unavailable to them. With the detailed data available through this partnership, it is expected that there will be improved study feasibility, leading to reduced screen failure rates and increased enrollment certainty.

This service offering includes a hybrid approach that seamlessly integrates brick-and-mortar sites, mobile sites, and in-home research. This unique collaboration between EmVenio Research, Prime Healthcare, and Health Wizz marks a significant milestone in EmVenio's evolution and service repertoire.

Wolfram believes that the EmVenio Research Center at Prime Healthcare will set them apart for patients, communities, partners, and clients alike. This partnership is expected to bring about positive changes in the world of clinical research by providing better opportunities for patients while also expanding research capabilities for healthcare providers.
Filed Under: Business

Show All News | Disclaimer | Report Violation

0 Comments
1000 characters max.

Latest on ncarol.com
  • K2 Global / Ozi Amanat Named Among Top 100 AI Venture Capitalists in 2026
  • Dr. Latorial Faison Appointed Poet Laureate of Virginia
  • Nautical Advisory Shares Buyer Perspective in Forbes Agency Council Webinar for Agency Founders
  • AdLeverage Brings Golf Simulator Contest and Home Services Marketing Expertise to Service World Expo 2026
  • Cleveland Factory Worker Seeks Funding for AI-Readable Archive Exploring Advanced AI Restraint and Human Survival
  • TradeJARnal Launches Innovative Trading Journal to Help Stock and Options Traders Build Discipline and Smarter Trading Habits
  • Pursant Founder Mark Herbick Joins STS Capital Partners as CEO
  • Tampa Holiday Sessions: Captured by Mallary Opens 2026 Christmas Minis With Two New Sets
  • Tampa Web Design Launches New Website for Entrepreneur and Capital Markets Advisor Martin Sumichrast
  • Miami Dade College and World Affairs Council of Miami announce Navarro-Cabrera scholarship
  • Nious Media Releases Debbie Bishop Interview on AI, Creativity, and Entertainment
  • RPP to host first Professional Padel Week in Miami and announce the 2026 USA Awards winners
  • UK Financial Ltd. Announces Maya Preferred PRA as First Fully Verified Asset on MAYA CHAIN; Chainlink Proof of Reserve Integration Planned for Network
  • ALight Technology And Services Limited Advances Through Peachscore + Dealum Accelerator and Join LvlUp Labs
  • International Misophonia Foundation Launches Sensory Accessible Technology Initiative to Address Overlooked Digital Accessibility Barriers
  • RAS AP Consulting Advances 1099 Education and Readiness Initiative Through IFOL Training and Finance Technology Showcase
  • Heritage at Manalapan Announces New 3.875% First-Year Mortgage Rate Buydown (7.11 APR)
  • AthleteMerch.com Surpasses 100,000 Custom Items Delivered to Fans Nationwide
  • Steve Weclew is Appointed by STS Capital Partners as Managing Director
  • New Finnish Affiliate Site Ilmaiskierrokset.com Puts Wager-Free Spins in the Spotlight
_catLbl0 _catLbl1

Popular on ncarol.com

  • Constantine "Costa" Kapothanasis II Acquires The Lubri-Loy Company, Carrying a 77-Year-Old American Lubricant Brand Into Its Next Era - 225
  • Parade of Homes Winners Announced - 205
  • LowSignalMail Lets Users Handle Gmail by Text Message - 202
  • North Carolina Author Carrie Sybert Celebrates Three Published Books - 168
  • Nious Media Expands Independent Entertainment Network Through Gaming, Music and Digital Storytelling - 160
  • RAS AP Consulting Issues National Compliance Alert and Launches Q4 2026 AP Readiness Program Ahead of IRS FIRE → IRIS Cutover - 148
  • Pregis Launches Sharp InfinX: On-Demand Rightsized Mailing System Delivering a Precision-Sized Mailer for Every Order - 143
  • Thunderbird F-16 Arrives 11/11 - 142
  • LCM Company Explains Professional Upholstery Cleaning in Charlotte, NC - 137
  • B Street Productions Announces Red Carpet Premiere Of Thriller "a Deadly Proposal" In North Car - 119

Similar on ncarol.com

  • Arizona Pest Control Surpasses $200,000 in Contributions to Southern Arizona High School Sports and Education Programs
  • ZenaTech (NAS DAQ: ZENA) $1 Million in New Utility Contracts- Potential $2.5 Million Follow-On Opportunity Puts Its Drone Business in the Spotlight!
  • New Patient Data Show REQORSA® Activating Cellular Repair Pathways as Roche Collaboration Advances Precision Lung Cancer Strategy for Genprex, Inc
  • Genuine Hospitality, LLC Selected to Operate Holiday Inn Express & Suites Jacksonville – Town Center
  • Shiokly Launches Online Marketplace to Help Singapore Home-Based Businesses Sell More, With First Product Listed Free
  • Freight Broker 911 and Milton Collier Introduce "What's The 911?"—A New Podcast Built on Real Talk, Real Freight, and Real Opportunity
  • PropAccount.com Launches PropWallet, Turning Prop Firm Payouts Into Repeat Sales
  • KOLBUS America, For All Of Your Hycorr Equipment And Service Needs
  • New TROP2 Research Breakthrough Strengthens REQORSA® Gene Therapy Story as Roche Collaboration Advances Precision Lung Cancer Treatment: Genprex, Inc
  • FDA Approval; Major Milestone for Preservative-Free Ketamine Ahead of FDA Goal Date for Treatment of Suicidal Depression by NRx Pharmaceuticals, Inc
Copyright © 2026 ncarol.com | Contact Us | Privacy Policy | Terms of Service | Contribute